Skip to content

Opus Genetics IRD Change in AR

Change in AR at other companies

AbbVie logo
AbbVieABBV
-$87M-106%
Opko Health logo
Opko HealthOPK
-$9.53M+58.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$1.2M+99.8%
Regenxbio logo
RegenxbioRGNX
-$18.25M-1,061%
Prime Medicine logo
Prime MedicinePRME
$0-100%
Precigen logo
PrecigenPGEN
$22.49M+12,950%

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's change in ar.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's change in AR?
Opus Genetics (IRD) reported change in AR of -$264K in Q1 2026.
How has Opus Genetics's change in AR changed year-over-year?
Opus Genetics's change in AR increased by 45.3% year-over-year, from -$483K to -$264K.
What does change in AR mean?
Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.